Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ron Sigourney who wrote (5930)	11/4/1998 11:31:00 AM
From: Diamondcutter	Read Replies (1) of 7041

FWIW, Deutsche Bank Securities held a Healthcare conference somewhere and had the following comments on ZONA's presentation. Please don't confuse information from opinion. The company outlined a full line of sexual dysfunction products in R&D, behind Vasomax, which will address moderate and severe male as well as female sexual dysfunction. The market size of male ED is $4 billion - $5 billion. DBS estimates that Vasomax has a $1 billion potential in worldwide peak sales (3-5 years from launch). The product pipeline addresses the urology and contraceptive markets. The Eproxal therapeutic vaccine is being studied to inhibit prostate tumor growth. Also, several new approaches are being developed for contraception, including the Zona and HCG vaccines, as well as Contrel. All these products are currently in preclinical trials. The company hopes to aggressively move these products into US clinical trials.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next